Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Electra currently has one program in clinical development and two additional preclinical programs. The company’s lead product candidate, ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and depletes pathological immune cells.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $84M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 18.02.2022 | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| 23.03.2022 | New Leaf V... | nlvpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 17.02.2022 | Series B | $84M | - | orbimed.co... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 17.02.2022 | Electra Therapeutics Raises $84M in Series B Financing | Electra Therapeutics, a South San Francisco, CA-based clinical stage biotechnology company, raised $... | finsmes.co... |
| 16.02.2022 | Electra Therapeutics Announces $84M Series B | SOUTH SAN FRANCISCO, CA, Electra Therapeutics, a biotechnology company, raised a $84M Series B fin... | vcnewsdail... |
| 13.02.2022 | Electra Therapeutics announces $84 million Series B financin... | - | orbimed.co... |